

1 **Evaluation of anti-SARS-CoV-2 antibody response to COVID-19 vaccine**
2 **deployment in the Bono Region, Ghana.**

3

4 **Short title:** Immune responses to COVID-19 vaccination in Ghana

5

6 **Samuel Fosu Gyasi^{1,2*}, Emmanuel Timmy Donkoh^{1,3*}, Samuel Frempong¹, Akwasi**
7 **Asamoah¹, Abdul Sakibu Raji¹, Rabbi Coffie Baidoo¹, Williams Isaac¹, Dorcas Essel¹ and**
8 **Herbert Alemiya Asakiya¹**

9

10 1. Center for Research in Applied Biology, CeRAB, University of Energy and Natural
11 Resources, Ghana

12

13 2. Dept of Biological Science, School of Science, University of Energy and Natural
14 Resources, Ghana

15

16 3. Dept. of Medical Laboratory Science, School of Science, University of Energy and
17 Natural Resources, Ghana

18

19 **Corresponding Authors:*

20 **Samuel Fosu Gyasi**, samuel.gyasi@uenr.edu.gh

21 **Emmanuel Timmy Donkoh**, timmy.donkoh@uenr.edu.gh

22

Abstract

Background: Preliminary data across the globe shows that the AstraZeneca vaccine was highly effective in preventing not only the symptoms but also the transmission of the SARS-CoV-2 virus. In Ghana, data on the immune response generated by different vaccination doses is lacking. The present study aimed to compare the anti-SARS-CoV-2 antibody response among single and double-vaccinated versus unvaccinated individuals. **Methods:** A case-control design was employed for this study. Seventy-nine participants (35 vaccinated, 44 unvaccinated) were recruited from the Sunyani West Municipality and screened for the presence of SARS-CoV-2 specific IgG and IgM antibodies in plasma samples using a Standard COVID IgG and IgM Combo FIA test. Data analysis was carried out with STATA (Version 21). **Results:** The current study showed that mean IgG levels among vaccine groups (Group-1: Not vaccinated, Group-2: 1 dose, Group-3: 2 doses) differed significantly ($F_{2,76}=11.457$, $p<.001$) between Group-1 and Group-3; and between Group-2 and Group-3. Participants in Group-2 and Group-3 were 4.1 and 12.5 times more likely to develop more antibody responses compared to their counterparts in Group-1 respectively. **Conclusion:** The study showed that participants who took one shot of the vaccine, as well as those who took two shots of the AstraZeneca Vaccine, were 4.1 and 12.5 times more likely to develop a greater antibody response than those who did not receive the vaccine respectively.

Keywords: *AstraZeneca Vaccine, SARS-CoV-2, Antibody Response, Humoral Immune Response, Ghana.*

23 INTRODUCTION

24 The emergence of COVID-19 caused by an enclosed, single-stranded, positive-sense RNA virus
25 (SARS-CoV-2) in Wuhan, China and its subsequent rise to a global pandemic has had a
26 tremendous impact on people's lives, causing severe disruption in health systems and having a
27 significant influence on the worldwide economy (1). More than 426,624,859 confirmed cases of
28 COVID-19 have been reported worldwide, with 5,899,578 deaths. So far, Africa has reported
29 8,303,144 cases with 169,288 deaths and Ghana has had over 159,006 confirmed cases of COVID-
30 19 with 1,442 deaths (WHO, 2021b). The unusual spike in cases worldwide is thought to be due
31 to limited pre-existing immunity(2).

32 Vaccination has historically proven to be one of the most effective methods of disease burden
33 alleviation and subsequent elimination (3-5). As of January 12, 2022, the WHO had reviewed and
34 approved nine COVID-19 vaccines for emergency use: AstraZeneca/Oxford, Johnson & Johnson,
35 Moderna, Pfizer/BioNTech, Sinopharm, Sinovac, Covaxin, Covovax, and Nuvaxovid (6).
36 Currently, six vaccines have been approved in Ghana: these are [1] AZD1222 Covishield
37 (Oxford/AstraZeneca); [2] ChAdOx1 nCoV-19 Vaxzevria (Oxford/AstraZeneca); [3] JNJ-
38 78436735 Janssen (Johnson & Johnson), [4] Gam-COVID-Vac Sputnik V (Gamaleya); [5]
39 BNT162b2 Comirnaty (Pfizer/BioNTech); [6] mRNA-1273 Spikevax (Moderna), with the
40 AstraZeneca/Oxford vaccine being the most widely deployed (7).

41 Vaccination provides population-level immunity to an infectious disease by creating an
42 immunological memory for a particular pathogen and inducing the production of protective
43 antibodies. As with other coronaviruses, the spike protein of SARS-CoV-2 is required for viral
44 attachment, fusion, entrance, and transmission. As such they serve as an ideal target for vaccine
45 development aimed at minimizing the spread of the disease (8-11). As a result, the antibody

46 response to spike protein post-vaccination is critical for adjudging the ‘effectiveness’ of the
47 vaccine (12). The detectable levels of IgM and IgG antibodies could provide information regarding
48 seroconversion, as the detection of IgM antibodies indicates a recent exposure whereas the
49 detection of IgG antibodies in the absence of detectable IgM antibodies indicates long-term
50 immunity against the virus (13). Results from COVID-19 AstraZeneca vaccine clinical trials
51 suggest that a single dose elicits an increase in spike-specific antibodies by day 28 and neutralizing
52 antibodies in all participants after a booster dose (14, 15).

53 There is a question about the effectiveness of the antibody response among vaccinated and
54 unvaccinated individuals in the African setting where the disease has not exacted as much a toll as
55 it has on other continents. However, very few studies have been undertaken to investigate the
56 humoral immune response to SARS-CoV-2 vaccines, specifically the AstraZeneca vaccine widely
57 deployed in Sub-Saharan Africa. In Ghana, studies assessing IgG and IgM antibody responses to
58 the AstraZeneca COVID-19 vaccination are severely lacking. The goal of this study, therefore,
59 was to compare the anti-SARS-CoV-2 antibody response among single and double-vaccinated
60 versus unvaccinated individuals in a peri-urban sub-Saharan community.

61

62 **MATERIALS AND METHODS**

63 **Study design and setting:** A case-control study of unmatched outcomes was conducted in the
64 Sunyani West Municipality of the Bono region of Ghana from November 2021 to November 2022
65 among individuals receiving the SARS CoV-2 vaccine (AZD1222, Oxford/AstraZeneca, Pune,
66 India) and control treatments (unvaccinated individuals) with 1 control per experimental subject.
67 The vaccine was administered as a 0.5 ml dose given intramuscularly into the deltoid muscle

68 (upper arm). Data available to our lab from the University community before mass vaccination
69 campaigns in the region indicates that the probability of seroconversion among unvaccinated
70 individuals is 0.2. If the true probability of seroconversion among vaccinated individuals is 0.6
71 (16), we will need to study 34 case patients and 34 control patients to be able to reject the null
72 hypothesis that the seropositivity rates for vaccinated and unvaccinated controls are equal with
73 probability (power) 0.9. The Type I error probability associated with this test of this null hypothesis
74 is 0.05. A continuity-corrected chi-squared statistic or Fisher's exact test will be used to evaluate
75 this null hypothesis at baseline and during follow-up.

76 Community members heard about the research through public announcements on radio and in
77 community fora. Individuals with PCR-confirmed prior infection, pregnant women, individuals
78 younger than 18 years, or seriously ill persons were not included in the study.

79

80 **Participants and Data collection:**

81 A detailed schematic of the study is provided in Figure 1. Study participants were recruited using
82 a multistage cluster sampling protocol in which the entire municipal health directorate was mapped
83 into clusters/enumeration areas (EA) based on data from the 2021 Population and Housing Census.
84 With support from the Ghana Health Service, three clusters were selected based on vaccination
85 coverage and another three unvaccinated clusters as controls. In each cluster, housing units with
86 eligible individuals were selected as follows: large sparse settlements were sub-divided into four
87 sectors using a sketch map and major landmarks (e.g. road, river, school, mosque, church, etc.).
88 One sector was randomly selected and its centre was identified. From the centre, a first housing
89 unit was identified by pen-spinning. Successive housing units were identified by serpentine
90 movement. Smaller settlements did not require an initial sub-division step.

91 The study was explained to all members of each housing unit and random number tables were used
92 to select a single eligible individual per housing unit for documentation of consent. An interviewer-
93 administrated questionnaire (designed using Kobo toolbox data collection tool version 2021.3.4 in
94 English) was used to capture participants' sociodemographic characteristics. Questions were asked
95 in simple language to ensure proper comprehension before answers were provided.

96

97 **Figure 1: Flow diagram illustrating nested case control design**

98

99 **Blood Sample Collection and Laboratory Analysis:** Venous blood (2-3ml) was collected via
100 venipuncture into labelled EDTA tubes from eligible participants by an experienced phlebotomist
101 at two prespecified time points: from day 21 to 28 ($t_0=0$) and from day 84 to 91 ($t_0=1$). The samples
102 collected from participants were transported on ice to the Centre for Research in Applied Biology
103 (CeRAB), centrifuged at 4000rpm for 5mins to separate the plasma into pre-labelled cryotubes
104 and stored at -20°C . Laboratory detection of anti-SARS-CoV-2 S1 spike protein-specific IgG and
105 IgM antibodies was performed using the STANDARD F COVID-19 IgM / IgG Combo FIA test
106 kits on the F2400 Analyzer (SD Biosensor, Inc., KOREA) according to the manufacturer's
107 guidelines.

108 The STANDARD F COVID-19 IgM / IgG Combo FIA detects IgG and IgM antibodies developed
109 against the SARS-CoV-2 S1 spike protein and has a sensitivity of 94.41% and specificity of
110 90.62% (17). A quantitative measure of the fluorescent signal emitted corresponding to the amount
111 of antibody present provides a basis for establishing seropositivity after establishing a
112 threshold/cut-off index. A cut-off index (COI) equal to or greater than 1.0 indicates a positive

113 result for anti-S1 SARS-CoV-2 IgG and IgM. The antibody index is a numerical representation of
114 the measured fluorescence signal given off by the test reaction that took place within the F2400
115 Analyzer.

116

117 **Ethical Consideration:** All research activities and protocols were approved by the Committee for
118 Human Research and Ethics at the University of Energy and Natural Resources with reference
119 number CHRE/AP/09/021. The purpose of the study and all procedures were explained to
120 participants before consent was taken. All participants were provided with informed consent forms
121 and were included after the endorsement of the form.

122

123 **Data Analysis and Processing:** Data was entered into Microsoft Excel 2016 for initial processing
124 and analyzed with STATA (Version 26). Mean and Standard deviation for quantitative variables
125 were calculated along with frequencies and percentages for all categorical variables. Multiple-way
126 ANOVA tests were performed to estimate the difference in antibody levels between individuals
127 vaccinated with one dose, two doses and unvaccinated individuals. The association between
128 variables such as sex, vaccination status, anti-S1 IgM, and IgG response were evaluated with the
129 Chi-square test of independence. Where required, anti-S1 IgG and IgM indices were compared
130 across categories by the Student's t-test. Logistic regression was performed to determine the odds
131 of anti-S1 IgG seropositivity across different dose categories. A p-value less than 0.05 was
132 considered statistically significant.

133

134

135 **RESULTS**

136 **Socio-Demographic information on participants**

137 At baseline 35 vaccinated and 44 non-vaccinated individuals fulfilled all criteria and were eligible
138 for follow-up. Baseline characteristics of the study population are shown in Table 1. The mean age
139 was 32 ±14.3 years. Participants were mostly males (65.8%). Common complaints post-
140 vaccination included pain at injection site (62.9%), headache (37.1) and malaise (25.8).

141

142 **Table 1: Baseline Characteristics of Study Participants**

Variable	n (%)
<i>Mean Age (SD)</i>	32 ±14.3
<i>Sex (n=79)</i>	
Males	52 (65.8)
Females	27 (34.2)
<i>Vaccination Status (n=79)</i>	
None	44 (55.7)
One dose	18 (22.8)
Two doses	17 (21.5)
<i>Post-vaccination adverse events (N=35)</i>	
Yes	25 (71.4)
No	10 (28.6)
<i>Common complaints (N=35)</i>	
Pain at injection site	22 (62.9)
Headache	13 (37.1)
Fever	8 (22.9)
General malaise	9 (25.8)
Chills	10 (28.6)
Arthralgia	1 (2.9)

143 **Footnote: N= 79**

144

145

146 **Prevalence of anti-S1 IgM and IgG among participants**

147 Baseline data on seroconversion to anti-S1 protein IgM and IgG for vaccinated and individuals
148 and controls are presented in Table 2. Among non-vaccinated individuals (13/44; 29.5%) anti-S1
149 IgM seropositivity was higher than was recorded for single (4/18; 22.2%) and double vaccinated
150 (1/17; 5.9%) individuals. Anti-S1 IgG titres were much higher across all three vaccination

151 categories. However, non-vaccinated individuals (24/44; 54.5%) had significantly lower anti-S1
152 IgG titres compared to single (15/18; 83.3%) and double vaccinated individuals (16/17; 94.1%)
153 [χ^2 (df=2, $N= 79$) = 11.15, $p = .004$].

154

155

156
157
158

Table 2: Prevalence of IgM and IgG anti-S1 antibody among participants

Parameter	Anti-S1 IgM		X ² - Value, df	P-Value	Anti S1 IgG		X ² - Value, df	P- Value
	Positive	Negative			Positive	Negative		
Vaccination Status								
No dose	13 (29.5)	31 (70.5)			24 (54.5)	20 (45.5)		
Single dose	4 (22.2)	14 (77.8)	3.91, 2	0.142	15 (83.3)	3 (16.7)	11.15, 2	0.004
Double dose	1 (5.9)	16 (94.1)			16 (94.1)	1 (5.9)		
Total	18 (22.8)	61 (77.8)			55 (69.6)	24 (30.4)		

159
160
161
162

Note: Anti-S1 IgM: Anti SARS-CoV-2 spike protein 1 immunoglobulin M, Anti-S1 IgG: Anti SARS-CoV-2 spike protein 1 immunoglobulin G, X²: Chi-square value, df: Degree of freedom. P-value considered significant at p<0.05.

163 To test the null hypothesis that antibody responses are similar across the various levels of vaccine
 164 dose, participants were divided into 3 (group 1: Not vaccinated, Group 2: 1 dose, Group 3: 2 doses)
 165 and mean titres compared by ANOVA (Table 3). Significant differences in the levels of antibody
 166 response were observed ($F_{2, 76}=11.46$, $p<.001$). Post-hoc comparisons to reveal heterogeneity
 167 between groups were performed using Dunnett's T3 as shown in Table 3 below. The mean COI
 168 for the unvaccinated group ($M=6.19$, $SD=6.42$) was significantly lower compared to the
 169 vaccinated group. However, the single-dose group's ($M=10.75$, $SD=6.39$) antibody response did
 170 not differ significantly from the double-dose group ($M=13.88$, $SD=3.56$).

171 **Table 3: Number of Doses Stratified by Test of Homogeneity of Variance**

<i>No. of doses</i>	Test of Homogeneity of Variance		ANOVA	
	<i>Mean</i>	<i>SD</i>	<i>F</i>	<i>Sig.</i>
None	6.19	6.42	11.46	0.000
1st Dose	10.75	6.39		
2nd Dose	13.87	3.56		

Differences between groups

<i>No. of doses</i>	<i>Mean Difference</i>	<i>Sig.</i>	<i>95% Confidence interval</i>
None- 1 dose	-4.56	0.046	-9.06. - -0.06
None- 2 doses	-7.68	0.000	-10.88 - -4.48

172
 173 Logistic regression was performed to determine the odds of anti-S1 IgG seropositivity across
 174 different dose categories (Table 4). Double vaccinated individuals were 4.1 times more likely to
 175 develop anti-S1 IgG seropositivity compared to unvaccinated individuals. Again, those who took
 176 two doses were 12.5 times more likely to develop anti-S1 IgG seropositivity than those without
 177 the vaccine.

178 **Table 4: Odds of anti-S1 IgG seropositivity**

Antibodies level	AOR (95%)	P-Value	CI
No. of Doses			
None	1	-	-
One dose	4.10	0.044*	1.04 - 16.27
Two doses	12.50	0.021*	1.48 - 105.52

179 *Footnote: * p-value<0.05, AOR: Adjusted Odds Ratio, CI: Confidence Interval,*

180 **DISCUSSION**

181 To the best of our knowledge, this is the first report from Ghana to report data on the SARS-CoV-2
182 antibody response following widespread community administration of Covishield by the Ghana
183 Health Service. Community vaccination does not only provide individual protection, but also
184 facilitates the attainment of herd immunity to protect immunocompromised, unvaccinated and
185 immunologically naïve individuals by lowering the number of vulnerable people below the
186 transmission threshold (18). Despite the high efficacy of most currently approved vaccines,
187 particularly in reducing the risk of clinical aggravation (19) accumulating data show significant
188 heterogeneity in the immune response elicited after vaccination among different individuals (18).

189 The acute phase antibody (IgM) showed no significant association with vaccination status (Table
190 2). A reason for this observation is that the anti-SARS-CoV-2 S1 IgM antibody can be acquired
191 through either natural infection or vaccination and is expected to wane rapidly over time (20, 21).
192 Therefore, in areas where viral exposure and vaccine coverage are high, anti S1 IgM antibody
193 titres may not vary significantly among these groups.

194 On the other hand, seroconversion to the chronic phase antibody (IgG) was associated with
195 significant variation among vaccination categories as reported in previous vaccine efficacy studies
196 (22). IgG levels are known to be critical in ensuring protection against viral diseases (23). Also,
197 IgG antibodies have a longer half-life and are the most commonly used in clinical settings as a
198 marker of long-term protection or vaccine efficacy (24).

199 Significant differences in the levels of antibody response were observed (Table 3). Post-hoc
200 comparisons revealed that antibody titres for the unvaccinated group were significantly low when
201 compared to the two vaccinated groups. However, we did not observe significant differences in

202 antibody titre between single vaccinated and double vaccinated individuals at baseline. This
203 phenomenon could be attributed to the time of sampling being too premature in the time course of
204 vaccination for any variability to be observed and can be clarified during follow-up (25). However,
205 in regression analysis, single and double vaccinated individuals were respectively 4.1 and 12.5
206 times more likely to have positive IgG antibody titres than vaccine-naïve participants (Table 4).

207

208 **CONCLUSION**

209 We have assessed the IgM and IgG SARS-CoV-2 spike protein antibody response between
210 vaccinated (single and double dose) and unvaccinated individuals in peri-urban communities in
211 Ghana. Initial results demonstrate that in the short-term taking one or two doses of the AstraZeneca
212 vaccine generates a significant protective antibody response over not taking the vaccine at all. It
213 remains to be seen how long the generated immune response lasts will last in this population and
214 whether a booster shot could be a useful strategy.

215

216

217 **DECLARATIONS**

218

219 **CONSENT FOR PUBLICATION**

220 All authors have duly consented for this manuscript to be submitted for publication

221

222 **AVAILABILITY OF DATA AND MATERIALS**

223 The data for this study is available in the manuscript and in its attached Supplementary File: **S1**

224 **File. Study Data.** It can also be obtained through the Committee for Human Research and Ethics

225 (CHRE) of the University of Energy and Natural Resources.

226

227 **FUNDING**

228 The authors have no funding to declare

229

230 **AUTHORS' CONTRIBUTION**

231 SFG conceived and designed the study and provided supervision, ETD contributed to the study

232 design, provided supervision and drafted the manuscript with AA. AA, ASR and SF undertook

233 sample collection, processing and performed laboratory analysis. RCB, DE and WI undertook

234 participant recruitment, field data collection and assisted with experimental testing in the

235 laboratory. HAA analyzed the data and reported the findings. All authors reviewed and approved

236 the final manuscript.

237

238 **ACKNOWLEDGEMENTS**

239 We wish to acknowledge the chiefs and people of the Fiapre community for their support during
240 this work.

241

242 **CONFLICT OF INTEREST**

243 The authors have no interests to declare.


244

REFERENCES

1. Singh S, Kumar R, Panchal R, Tiwari MK. Impact of COVID-19 on logistics systems and disruptions in food supply chain. *International Journal of Production Research*. 2021;59(7):1993-2008.
2. Sette A, Crotty S. Author Correction: Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. *Nature reviews Immunology*. 2020;20(10):644.
3. Bloom DE. The value of vaccination. *Hot topics in infection and immunity in children VII*: Springer; 2011. p. 1-8.
4. Echeverria-Londono S, Li X, Toor J, de Villiers MJ, Nayagam S, Hallett TB, et al. How can the public health impact of vaccination be estimated? *BMC Public Health*. 2021;21(1):1-12.
5. Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. *BMC Public Health*. 2014;14:813.
6. WHO. COVID-19 advice for the public: Getting vaccinated 2022 [Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice>].
7. Baffoe GA, Nortey NKLW. An Analysis of Conspiracy Beliefs of Covid-19 Vaccination in Ghana. *Advances in Journalism Communication*. 2021;9(4):196-208.
8. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV — a target for vaccine and therapeutic development. *Nature Reviews Microbiology*. 2009;7(3):226-36.
9. Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. *Expert opinion on therapeutic targets*. 2017;21(2):131-43.
10. Wu W, Wang A, Liu M. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
11. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. *Trends in immunology*. 2020;41(5):355-9.
12. Raturi M, Kusum A, Kala M, Mittal G, Sharma A, Bansal N. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants. *Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine*. 2021;28(3):300-2.

13. Jamiruddin R, Haq A, Khondoker MU, Ali T, Ahmed F, Khandker SS, et al. Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh. *Expert review of vaccines*. 2021;20(12):1651-60.
14. Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *The New England journal of medicine*. 2021;385(25):2348-60.
15. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet*. 2020;396(10249):467-78.
16. Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. Longitudinal monitoring of SARS-CoV-2 IgM and IgG seropositivity to detect COVID-19. *The journal of applied laboratory medicine*. 2020;5(5):908-20.
17. Biosensor S. Standard F COVID-19 IgM/IgG Combo FIA. In: Biosensor S, editor. Package insert2019.
18. Mallory ML, Lindesmith LC, Baric RS. Vaccination-induced herd immunity: successes and challenges. *Journal of Allergy Clinical Immunology*. 2018;142(1):64-6.
19. Doroftei B, Ciobica A, Ilie O-D, Maftai R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. *Diagnostics*. 2021;11(4):579.
20. Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. *Nature communications*. 2021;12(1):1-11.
21. Banga Ndzouboukou JL, Zhang YD, Lei Q, Lin XS, Yao ZJ, Fu H, et al. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. *Curr Med Sci*. 2021;41(6):1081-6.
22. Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. *Nat Microbiol*. 2021;6(9):1140-9.
23. Murin CD, Wilson IA, Ward AB. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. *Nature microbiology*. 2019;4(5):734-47.
24. Racine R, Winslow GM. IgM in microbial infections: taken for granted? *Immunology letters*. 2009;125(2):79-85.

25. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. *Clinical translational immunology*. 2020;9(5):e1136.



Figure